SGAM
KERX

Smith Group Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Smith Group Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-82,100
Closed -$1.4M – 466
2014
Q1 		$1.4M Buy
+82,100
New +$1.24M 0.05% 171

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Smith Group Asset Management's KERX Position: Q2 2014 in Review

Smith Group Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2014, closing a stake of 82,100 shares — an estimated $1.4M sold.

Smith Group Asset Management first reported a position in KERX in Q1 2014 and held it in 1 quarter. The position peaked at $1.4M in Q1 2014. 135 funds tracked by Wall St. Rank hold KERX as of Q2 2014.

  • Smith Group Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Smith Group Asset Management sold 82,100 Keryx Biopharmaceuticals Inc shares in Q2 2014, an estimated $1.4M.
  • Smith Group Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 1 quarter.
  • Smith Group Asset Management's Keryx Biopharmaceuticals Inc position peaked at $1.4M in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2014.

Based on Smith Group Asset Management's 13F filing for Q2 2014, filed 23 Jul 2014.